Friday, March 13, 2026 | 10:20 AM ISTहिंदी में पढें
Anthem Biosciences Ltd News
Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms
While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs
 "Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms")
Updated On : 09 Jan 2026 | 11:20 AM IST
Nomura initiates Anthem with 'Buy', sees strong long-term CRDMO runway
The brokerage cited the company's strong positioning in India's fast-growing CRDMO space, high profitability and disciplined execution as reasons for its bullish view
 "Nomura initiates Anthem with 'Buy', sees strong long-term CRDMO runway")
Updated On : 28 Nov 2025 | 8:33 AM IST